Richard Hynes, Renowned Cancer Biologist Who Decoded Cellular Adhesion, Dies at 81

Richard O. Hynes, the MIT Professor Emeritus whose pioneering work on cellular adhesion redefined cell biology and contributed to modern cancer treatments, died on January 6 at 81. Over more than five decades, Hynes' discoveries—especially his identification of integrins, a family of cell-surface receptors central to cell adhesion—crucially shaped research in developmental biology, cancer, fibrosis, and immune disorders.

A Titan in Cancer Biology and Mentorship

Hynes was the Daniel K. Ludwig Professor for Cancer Research (Emeritus) at MIT, a key member of the Koch Institute for Integrative Cancer Research, and an affiliate of the Broad Institute. His leadership played a defining role during transformative periods in cancer research at MIT and far beyond. As Matthew Vander Heiden, current director of the Koch Institute, reflected: “The research from his laboratory launched an entirely new field by defining the molecules that mediate interactions between cells and their environment. This laid the groundwork for better understanding the immune system and metastasis.”

Early Life: Science from the Start

Born in Kenya and raised in Liverpool, Hynes grew up in a family steeped in scientific inquiry: his father, a freshwater ecologist; his mother, a physics teacher. Early family discussions cultivated a curiosity that propelled him into biology at Cambridge University—a hotbed of post-DNA breakthrough research in the 1960s. His academic journey led him across the Atlantic to MIT, where he undertook doctoral research and later faculty roles, deeply influencing the Institute’s scientific trajectory.

Defining Cellular Connections

Hynes’ hallmark achievement was the discovery and characterization of integrins and the protein fibronectin—cornerstones of the extracellular matrix (ECM) that both bind cells together and anchor them within tissues. By mapping how cells adhere and communicate, Hynes helped answer fundamental biological questions: how do tissues hold together, and how do cells migrate appropriately during development or disease?

His work showed that loss of cell adhesion—the ability of cells to “stick”—is instrumental in the spread of cancer (metastasis). By identifying the molecular machinery involved, Hynes paved the way for new diagnostic and therapeutic strategies. Integrins, now known to exist in at least 24 varieties in humans, are vital for clotting, development, and immune function. Insights from Hynes’ lab contributed to the development of treatments for autoimmune diseases, including multiple sclerosis.

Innovations in Cancer and Beyond

Hynes’ laboratory advanced research technologies, such as proteomic methods to isolate and analyze components of the ECM. These advances allowed him and his team to link specific proteins to cancer prognosis, progression, and response to therapy. His studies elucidated how certain ECM proteins promote or suppress tumor growth, influence the effectiveness of immunotherapy, and facilitate the spread of cancerous cells.

Among his numerous contributions, Hynes's work led to identifying cell adhesion molecules as biomarkers and exploring them as drug targets for cancer and fibrotic diseases. The biotech firm Matrisome Bio, co-founded with his former postdoctoral fellow Noor Jailkhani, continues this legacy—developing targeted therapies that harness ECM science.

Leadership and Lasting Influence

Beyond the laboratory, Hynes was admired as a mentor and academic leader. He served as head of MIT’s Department of Biology and as director of the MIT Center for Cancer Research, roles in which he shaped interdisciplinary programs and cultivated new generations of researchers. Notably, his influence reached international policy: Hynes co-chaired committees on research ethics and stem cell guidelines, and served as a scientific governor at the Wellcome Trust in the UK.

Peers and protégés remember his intellectual generosity, personal kindness, and commitment to educational excellence. As Amy Keating, head of MIT’s Department of Biology, recalled: "Richard was happy to share stories, perspectives, and advice, always with a twinkle in his eye that conveyed his infinite interest in … science, scientists, and life itself.”

Honours and Recognition

Hynes’s pioneering impact earned him a raft of accolades, including the 2022 Albert Lasker Basic Medical Research Award (shared with research partners Erkki Ruoslahti and Timothy Springer), the Canada Gairdner International Award, and membership in leading learned societies such as the National Academy of Sciences and the Royal Society of London.

A European Touch, a Global Legacy

Though his career flourished in the United States, Hynes’ British roots shaped his approach and bridged transatlantic scientific communities. His policy work, matched with a focus on mentorship, ensured lasting influence on European and international science standards.

Richard Hynes is survived by his wife Fleur, their sons Hugh and Colin, and four grandchildren. His scientific insights ripple far beyond MIT—embedded in treatments, research programs, and in the minds of the many he taught and inspired.

Read more at MIT News.